ARX788 in HER2-positive, Metastatic Breast Cancer Subjects (ACE-Breast-03)
Public ClinicalTrials.gov record NCT04829604. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Global, Phase 2 Study of ARX788 in HER2-positive Metastatic Breast Cancer Patients Who Were Previously Treated With T-DXd
Study identification
- NCT ID
- NCT04829604
- Recruitment status
- Active, not recruiting
- Study type
- Interventional
- Phase
- Phase 2
- Lead sponsor
- Ambrx, Inc.
- Industry
- Enrollment
- 72 participants
Conditions and interventions
Conditions
Interventions
- ARX788 Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Oct 25, 2021
- Primary completion
- Nov 30, 2026
- Completion
- May 31, 2027
- Last update posted
- Mar 8, 2026
2021 – 2027
United States locations
- U.S. sites
- 25
- U.S. states
- 16
- U.S. cities
- 25
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Research Site | Los Angeles | California | 90033 | — |
| Research Site | Newport Beach | California | 92663 | — |
| Research Site | San Francisco | California | 94158 | — |
| Research Site | Whittier | California | 90602 | — |
| Research Site | Atlanta | Georgia | 30322 | — |
| Research Site | Chicago | Illinois | 60611 | — |
| Research Site | Louisville | Kentucky | 40207 | — |
| Research Site | Silver Spring | Maryland | 20904 | — |
| Research Site | Boston | Massachusetts | 02215 | — |
| Research Site | St Louis | Missouri | 63110 | — |
| Research Site | Omaha | Nebraska | 68130 | — |
| Research Site | Las Vegas | Nevada | 89128 | — |
| Research Site | Camden | New Jersey | 08103 | — |
| Research Site | New Hyde Park | New York | 11042 | — |
| Research Site | New York | New York | 10028 | — |
| Research Site | Shirley | New York | 11967 | — |
| Research Site | The Bronx | New York | 10469 | — |
| Research Site | Portland | Oregon | 97213 | — |
| Research Site | Tigard | Oregon | 97223 | — |
| Research Site | Philadelphia | Pennsylvania | 19104 | — |
| Research Site | Dallas | Texas | 75246 | — |
| Research Site | Houston | Texas | 77030 | — |
| Research Site | San Antonio | Texas | 78229 | — |
| Research Site | Norfolk | Virginia | 23502 | — |
| Research Site | Tacoma | Washington | 98405 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 8 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT04829604, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Mar 8, 2026 · Synced May 19, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT04829604 live on ClinicalTrials.gov.